SomaLogic

About SomaLogic

SomaLogic was founded in 2000 by Larry Gold, with the goal of improving the quality of life of every individual by transforming how health was assessed and managed, based on the precise measurement of changes in the body's proteins.

Our Vision
Empowering a healthier world — one protein scan at a time

Our Mission
We scan the living data stream of human proteins with greater precision, sensitivity and scale than anybody in the world, and translate it into actionable insights for every seeker and enabler of human health.

Notable Facts

- Privately-held biotechnology company
- Based in Boulder, Colorado
- Larry Gold, Ph.D., *Founder and Chairman of the Board*
- Roy Smythe, M.D., *Chief Executive Officer*
- 220 employees worldwide
- >600 issued and pending patents
- >200 scientific publications from SomaLogic and third-party users

Proteins are the key to understanding and managing health and disease

Proteins (e.g. enzymes, hormones, antibodies, drug receptors, etc.) give our cells structure, guide development, allow the body to move, help fight infection, transport molecules such as oxygen, and regulate complex systems such as blood sugar and mood. The levels of proteins within various parts of the body are constantly changing in response to factors such as diet, aging, drug treatments, microorganisms, and stress. These changes in protein levels provide meaningful insights into a person's state of health and wellness at any specific time and can rapidly determine whether health interventions are working.

The SOMAscan® Platform: from protein measurements to health insights

There are thousands of proteins circulating within the body at any given time, and they are present at vastly different concentrations. SomaLogic's proprietary, SOMAscan® assay is the only proteomic technology that can measure broadly (~5000 proteins simultaneously), deeply (high- and low-abundance proteins), and rapidly (high throughput) in a small sample volume.

SomaLogic is working with leading academic institutions and biobanks around the world to assemble the world's largest database of protein measurements, applying our SOMAscan® assay to thousands of samples with extensive clinical outcome data. We are using state-of-the-art machine learning and bioinformatics capabilities to transform this massive collection of data into quantitative risk assessments and reliable physiological and lifestyle insights. Our SOMAscan® platform is being applied to wide range of diseases and conditions to deliver insights that enable biomarker discovery, diagnostics development, and pharmaceutical discovery and development, and health management.

▷ RIGHT   ▷ TIME   ▷ HEALTH

Selected Publications:

1. Ganz, P *et al.* (2016) "Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease." *Journal of the American Medical Association* **315**(23): 2532-2541.

2. Ngo, D *et al.* (2016) "Aptamer-based proteomic profiling reveals novel candidate biomarkers and pathways in cardiovascular disease." *Circulation* **134**(4): 270-285.

3. Jacob, J *et al.* (2017) "Application of large scale aptamer-based proteomic profiling to "planned" myocardial infarctions." *Circulation* **137**(12): 1270-1277.

4. Williams, SA *et al.* (2018) "Improving assessment of drug safety through proteomics: early detection and mechanistic characterization of the unforeseen harmful effects of Torcetrapib." *Circulation* **137**(10): 999-1010.

5. Benson, MD *et al.* (2018) "Genetic architecture of the cardiovascular risk proteome." *Circulation* **137**(11): 1158-1172.

6. Sun, BB *et al.* (2018) "Genomic atlas of the human plasma proteome." *Nature* **558**: 73-79.

7. Emilsson, V *et al.* (2018) "Co-regulatory networks of human serum proteins link genetics to disease." *Science* **361**(6404): 769-773.

Website: www.somalogic.com
Twitter: www.twitter.com/somalogic
LinkedIn: www.linkedin.com/company/somalogic

Press contact: mediacontact@somalogic.com